[1] Koren Gideon, King Susan, Knowles Sandra, et al.Ribavirin inthe treatment of SARS: A new trick for an old drug?[J]. CMAJ,2003, 168(10):1289-1292. [2] Momattin H, Mohammed K, Zumla A, et al.Therapeutic optionsfor Middle EastRespiratory Syndrome Coronavirus (MERS-CoV)-possible lessons from asystematic review of SARS-CoV therapy[J].International Journal of Infectious Disease, 2013, 17(10): e792-e789. [3] 田占红,王晨,郑然,等.磷酸奥司他韦联合抗病毒合剂对流感病毒感染患者的临床疗效[J/OL].中华医院感染学杂志,2020(2):288-291. [2020-02-22]. http://kns.cnki.net/kcms/detail/11.3456.r.20200113.2019.058.html. [4] Matsuyama Ryota, Nishiura Hiroshi, Kutsuna Satoshi, et al.Clinical determinants of the severity of Middle East respiratorysyndrome (MERS): a systematic review and meta-analysis[J].BMC Public Health, 2016, 16(1):1203. [5] 江华, 邓洪飞, 王宇, 等. 洛匹那韦/利托那韦(LPV/r)用于2019新型冠状病毒肺炎的治疗可能性:基于既往冠状病毒肺炎研究的快速系统评价[J]. 中华急诊医学杂志, 2020, 29(2):182-186. [6] Huang Kao-Jean, Su Ih-Jen, Theron Michel, et al.An interferon-gamma-related cytokine storm in SARS patients[J]. J Med Virol,2005, 75(2):185-194. [7] 陈岷,童荣生,边原,等.皮下注射α-干扰素治疗2019年新型冠状病毒的循证快速评估[J/OL].医药导报:1-19[2020-03-02].http://kns.cnki.net/kcms/detail/42.1293.R.20200210.1759.002.html. [8] Bulgakova VA, Poromov AA, Grekova AI, et al.Pharmacoepide-miological study of the course of influenza and other acute respiratoryviral infections in risk groups[J]. Ter Arkh, 2017, 89(1): 62-71. [9] Gregory PC, Kuhlemeier KV .Prevalence of Venous Thrombo-embolism in Acute emorrhagic and Thromboembolic Stroke[J].American Journal of Physical Medicine & Rehabilitation, 2003,82(5):364-369. [10] van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, casefatality, and functional outcome of intracerebral haemorrhageover time, according to age, sex, and ethnic origin: a systematicreview and meta-analysis[J]. Lancet Neurology, 2010, 9(2):167-176. [11] Hemphill J Claude, Greenberg Steven M, Anderson Craig S,et al.Guidelines for the Management of Spontaneous IntracerebralHemorrhage: A Guideline for Healthcare Professionals From theAmerican Heart Association/American Stroke Association[J].Stroke, 2015, 46(7):2032-2060. [12] 徐佳强,曾芳,吴艳,等.新型冠状病毒感染肺炎重症患者的营养支持及监护建议[J/OL].中国医院药学杂志:1-3. [2020-02-22].http://kns.cnki.net/kcms/detail/42.1204.r.20200218.0954.002.html. [13] 肖颖彬. 重视新型冠状病毒肺炎对心脏的损害[J].西部医学,2020, 32(3):313-315. [14] 赵荣生,杨毅恒,杨丽,等. 新型冠状病毒防控的药学工作指导与管理策略[J/OL].中国药学杂志:1-31.[2020-02-22].http://kns.cnki.net/kcms/detail/11.2162.R.20200207.0936.002.html. [15] 中华医学会临床药学分会《雾化吸入疗法合理用药专家共识》编写组. 雾化吸入疗法合理用药专家共识(2019年版)[J]. 医药导报, 2019, 38(2):135-146. [16] 王丹丹,史长松.干扰素生物学作用及雾化治疗研究进展[J].现代临床医学, 2018, 44(6):474-476. [17] Russell CD, Millar JE, Baillie JK.Clinical evidence does notsupport corticosteroid treatment for 2019-nCoV lung injury[J].Lancet, 2020, 395(10223):473-475. [18] 《内科住院患者静脉血栓栓塞症预防的中国专家建议》写作组,中华医学会老年医学分会,中华医学会呼吸病学分会,等.内科住院患者静脉血栓栓塞症预防中国专家建议(2015)[J].中华老年医学杂志, 2015, 34(4):345-352. [19] 刘子涵,郑恩来,张凤,等.血管紧张素转换酶2对心血管系统疾病影响的研究进展[J].中国老年学杂志, 2019, 39(6):1520-1522. [20] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hos-pitalized Patients With2019 Novel Coronavirus-Infected Pneu-monia in Wuhan, China[J]. JAMA, 2020, in press. DOI: 10.1001/jama.2020.1585. |